2016 Biomedtracker ASCO Survey
2016 Biomedtracker ASCO Survey
$599.00
Biomedtracker performed a 5-question survey of 39 United States and European (France, Germany, Italy, and United Kingdom) oncologists after the American Society of Clinical Oncology (ASCO) meeting to gauge interest in new data presented on drugs in clinical development.
Publisher: Biomedtracker
- Description
- Samples
Biomedtracker performed a 5-question survey of 39 United States and European (France, Germany, Italy, and United Kingdom) oncologists after the American Society of Clinical Oncology (ASCO) meeting to gauge interest in new data presented on drugs in clinical development.
Candidate drugs and indications covered include: abemaciclib (Eli Lilly) and Ibrance (Pfizer) for breast cancer, RG788 and Tecentriq (Roche) for solid tumors, and avelumab (Merck) for mesothelioma.
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
U.S. Markets for Respiratory Care Products, June 2016 
Sign up to the